As of February 11, 2026, Swissmedic announced a recall of Similasan Schlafstörungen Globuli due to quality issues affecting the product’s intended performance and safety. This recall affects batch number 17911 and is initiated at the patient level.
Navigation
What changed?
The recall is a result of a quality issue that may compromise the product’s intended purpose and safety. Swissmedic has initiated the recall to ensure patient safety and maintain public trust in the Swiss market.
Who is affected?
The recall affects patients who have been prescribed Similasan Schlafstörungen Globuli, specifically batch number 17911. Healthcare professionals and pharmacies are also impacted, as they must take steps to return the affected product and notify patients.
What are the implications?
The recall has significant implications for the manufacturer, as it may impact their reputation and lead to financial losses. Additionally, the recall highlights the importance of robust quality control measures in the pharmaceutical industry.
Quality control measures
Swissmedic emphasizes the need for manufacturers to implement effective quality control measures to prevent such issues in the future. This includes regular testing, inspection, and monitoring of products to ensure they meet the required standards.
Frequently Asked Questions
- What is the reason for the recall?
The recall is due to a quality issue that may compromise the product’s intended purpose and safety. - Which batch number is affected?
Batch number 17911 is affected. - What should patients do if they have been prescribed the affected product?
Patient’s should contact their healthcare professional or pharmacy for guidance on returning the product and obtaining a replacement.
Conclusion
In conclusion, the recall of Similasan Schlafstörungen Globuli highlights the importance of quality control measures in the pharmaceutical industry. Manufacturers must prioritize patient safety and take proactive steps to prevent such issues in the future.
Disclaimer
This article is for informational purposes only and should not be considered as legal advice. Healthcare professionals and patients should consult the official Swissmedic announcement and relevant guidelines for detailed information.